Login to MyKarger

New to MyKarger? Click here to sign up.

Login with Facebook

Forgot Password? Reset your password

Authors, Editors, Reviewers

For Manuscript Submission, Check or Review Login please go to Submission Websites List.

Submission Websites List

Institutional Login (Shibboleth)

For the academic login, please select your country in the dropdown list. You will be redirected to verify your credentials.

Table of Contents
Vol. 6, No. 1-2, 2006
Issue release date: April 2006
Section title: Review
Pancreatology 2006;6:17–32

International Consensus Guidelines for Management of Intraductal Papillary Mucinous Neoplasms and Mucinous Cystic Neoplasms of the Pancreas

Tanaka M.a · Chari S.b · Adsay V.c · Fernandez-del Castillo C.d · Falconi M.e · Shimizu M.f · Yamaguchi K.a · Yamao K.g · Matsuno S.h
aDepartment of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; bDepartment of Gastroenterology, Mayo Clinic, Rochester, Minn., USA; cDepartment of Pathology, Wayne State University and The Karmanos Cancer Center, Harper Hospital, Detroit, Mich., USA; dDepartment of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Mass., USA; eDepartment of Surgery, Verona University, Verona, Italy; fDepartment of Pathology, Saitama Medical School, Saitama, Japan; gDepartment of Gastroenterology, Aichi Cancer Center, Nagoya, Japan, and hDepartment of Gastroenterological Surgery, Graduate School of Medicine, Tohoku University, Sendai, Japan
email Corresponding Author

Masao Tanaka, MD, PhD, FACS

Department of Surgery and Oncology

Graduate School of Medical Sciences, Kyushu University

Fukuoka 812-8582 (Japan)

Tel. +81 92 642 5437, Fax +81 92 642 5457, E-Mail masaotan@med.kyushu-u.ac.jp

Do you have an account?

Login Information

Contact Information

I have read the Karger Terms and Conditions and agree.


Non-inflammatory cystic lesions of the pancreas are increasingly recognized. Two distinct entities have been defined, i.e., intraductal papillary mucinous neoplasm (IPMN) and mucinous cystic neoplasm (MCN). Ovarian-type stroma has been proposed as a requisite to distinguish MCN from IPMN. Some other distinct features to characterize IPMN and MCN have been identified, but there remain ambiguities between the two diseases. In view of the increasing frequency with which these neoplasms are being diagnosed worldwide, it would be helpful for physicians managing patients with cystic neoplasms of the pancreas to have guidelines for the diagnosis and treatment of IPMN and MCN. The proposed guidelines represent a consensus of the working group of the International Association of Pancreatology.

© 2006 S. Karger AG, Basel and IAP

Article / Publication Details

First-Page Preview
Abstract of Review

Received: March 29, 2005
Accepted: July 20, 2005
Published online: April 20, 2006
Issue release date: April 2006

Number of Print Pages: 16
Number of Figures: 10
Number of Tables: 4

ISSN: 1424-3903 (Print)
eISSN: 1424-3911 (Online)

For additional information: http://www.karger.com/PAN

Copyright / Drug Dosage / Disclaimer

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.